| Followers | 238 |
| Posts | 15504 |
| Boards Moderated | 1 |
| Alias Born | 03/29/2014 |
Friday, September 24, 2021 1:05:02 PM
While Cognate's headquarters had been in Maryland, they originally operated a GMP facility out of Sunnyvale in California.
Cognate BioServices, Inc. is a fully integrated contract bioservices organization providing the highest level of scientific and management expertise to its clients who are focused on the commercialization of cell- based products. Its comprehensive service package supports new and developing companies in the specific areas of preclinical research, assay development, regulatory services, process development, cGMP cell-based manufacturing, environmental health & safety, and laboratory support services. In addition to the corporate headquarters in Baltimore, Maryland, Cognate BioServices operates a GMP manufacturing facility in Sunnyvale, California. For more information visit the company's website at www.cognatebioservices.com.
https://www.biospace.com/article/releases/cognate-therapeutics-inc-changes-name-to-cognate-bioservices-inc-/
I can't remember which company had initially built the Memphis building (I think it was a failed pharma company), however, whoever it was then sold it to Cognate, and they moved the manufacturing there from Sunnyvale.
Her Toucan Capital has certainly been around for quite some time. This article, initially dated in 2001, discusses how some of the funds were gathered to invest in earl stage investments.
https://www.bizjournals.com/oldmht/stories/2001/01/29/story51.html
Then in 2006, the ED of the Maryland Technology Development Corp, leaves that company to join Toucan with the article stating, "Singerman called Toucan Capital the most effective early-stage private fund he'd worked with in more than two decades of economic development work. "There was a real fit between what they were doing and my experience," Singerman said in an interview.
https://www.bizjournals.com/baltimore/stories/2006/01/16/daily16.html
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
